NeoGenomics (NASDAQ:NEO) Issues FY 2025 Earnings Guidance

NeoGenomics (NASDAQ:NEO) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.150-0.190 for the period, compared to the consensus estimate of 0.200. The company issued revenue guidance of $735.0 million-$745.0 million, compared to the consensus revenue estimate of $735.0 million.

Wall Street Analyst Weigh In

NEO has been the subject of a number of analyst reports. Needham & Company LLC reduced their price objective on shares of NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Jefferies Financial Group began coverage on NeoGenomics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target for the company. Bank of America lowered their price objective on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 19th. Benchmark cut NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Piper Sandler reduced their price objective on shares of NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, NeoGenomics presently has an average rating of “Moderate Buy” and an average price target of $19.60.

NeoGenomics Stock Up 3.8 %

Shares of NASDAQ NEO opened at $10.54 on Friday. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -17.00 and a beta of 1.23. NeoGenomics has a 12-month low of $8.98 and a 12-month high of $19.11. The company has a current ratio of 1.98, a quick ratio of 1.91 and a debt-to-equity ratio of 0.38. The firm’s 50-day moving average price is $13.92 and its 200-day moving average price is $15.08.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). The company had revenue of $172.00 million for the quarter, compared to analysts’ expectations of $173.40 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. On average, equities research analysts anticipate that NeoGenomics will post -0.2 EPS for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.